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Chaperone-mediated autophagy (CMA) represents a selective form of autophagy
involved in the degradation of specific soluble proteins containing a pentapeptide motif
that is recognized by a cytosolic chaperone able to deliver proteins to the lysosomes
for degradation. Physiologically, CMA contributes to maintain crucial cellular functions
including energetic balance and protein quality control. Dysfunctions in CMA have been
associated to the pathogenesis of several neurodegenerative diseases characterized by
accumulation and aggregation of proteins identified as CMA substrates. In particular,
increasing evidence highlights the existence of a strong relationship between CMA
defects and Parkinson’s disease (PD). Several mutations associated with familial forms
of PD (SNCA, LRRK2, UCHL1 and DJ-1) have been demonstrated to block or reduce
the activity of CMA, the main catabolic pathway for alpha-synuclein (asyn). CMA
dysfunctions also leads to a mislocalization and inactivation of the transcription factor
MEF2D that plays a key-role in the survival of dopaminergic neurons. Furthermore,
reduced levels of CMA markers have been observed in post mortem brain samples from
PD patients. The aim of this review article is to provide an organic revision of evidence
for the involvement of CMA dysfunctions in the pathogenesis of PD. Updated findings
obtained in patient’s specimens will be resumed, and results deriving from in vivo and
in vitro studies will be discussed to evidence the current knowledge on the molecular
mechanisms underlying CMA alterations in PD. Finally, the possibility of up-regulating
CMA pathway as promising neuroprotective strategy will be considered.
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PARKINSON’S DISEASE IS A PROTEINOPATHY
Parkinson’s disease (PD), as well as other neurodegenerative diseases, belongs to the large category
of proteinopathies, conditions characterized by the presence of proteinaceous inclusions within
the degenerating neurons. The identification of such aggregates supports the view that misfolded
proteins represent a basic requirement for the neurodegenerative process and provided input to
verify the existence of possible dysfunctions of the biological systems influencing neuronal protein
homeostasis. Considering the post-mitotic nature of neurons, a proper activity of the intracellular
protein degradation systems appears to be crucial to ensure the maintenance of cell homeostasis
and to prevent the onset of the neurodegeneration.
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In PD, alpha-synuclein (asyn) has been proposed as the
central pathogenic protein, based on its identification as the
main component of the intraneuronal aggregates, known as
Lewy bodies, that represent a neuropathological hallmark of PD
(Spillantini et al., 1997). The accumulation of aggregated asyn
has been related to defects in the two major protein catabolic
systems (Xilouri et al., 2013b), the ubiquitin-proteasome system
(UPS) and the autophagy-lysosome pathway (ALP), represented
bymacroautophagy, chaperone-mediated autophagy (CMA) and
microautophagy.
Currently, the exact contribution of UPS and ALP to asyn
degradation remains unclear. There is a general consensus on
the view that, while UPS degrades only small and soluble
oligomers of asyn, ALP becomes crucial in pathologic conditions
(Ebrahimi-Fakhari et al., 2011). Furthermore, as the activity of
UPS and ALP appears functionally connected, dysfunctions in
one of these systems directly influence the other (Ding et al.,
2007; Pandey et al., 2007; Korolchuk et al., 2009; Qiao and Zhang,
2009). Alterations of both UPS and macroautophagy have been
reported in PD patients. Specifically, structural and functional
alterations in the 20S proteasome subunit was demonstrated
in post mortem substantia nigra of patients with sporadic PD
(McNaught and Olanow, 2003), and an increased number of
autophagic vacuoles was found in melanized neurons of the
substantia nigra in PD patients (Anglade et al., 1997). After the
demonstration that the efficiency of CMA pathway is crucial in
regulating the intraneuronal levels of asyn (Cuervo et al., 2004;
Mak et al., 2010), dysfunctions in this selective catabolic pathway
have been identified as important pathogenic contributors to PD,
as discussed in the following sections.
MOLECULAR CHARACTERISTICS OF CMA
AND PHYSIOLOGICAL FUNCTIONS
CMA is a selective catabolic pathway which allows the
degradation of specific cellular proteins. This feature makes
CMA an efficient way to remove specific damaged or abnormal
proteins and becomes an essential key-regulator in multiple
cellular processes. Substrates eligible to be degraded by
this pathway, including asyn, contains in their sequence a
pentapeptide conserved motif biochemically related to KFERQ
(Dice, 1990). This motif is selectively recognized by the cytosolic
chaperone heat shock cognate protein of 70 kDa, hsc70, which
binds the substrate and translocates it to the lysosomemembrane
(Chiang et al., 1989). Hsc70, in association with a specific subset
of molecular co-chaperones, participates to the unfolding of the
substrate protein, an essential requirement for translocation to
the lysosomes (Agarraberes and Dice, 2001). After the binding
to the chaperones, the substrate is targeted to the lysosomal
membrane where it interacts with the lysosome-associated
membrane protein type 2A (lamp2A; Cuervo and Dice, 1996).
Lamp2A, in association with other proteins, forms a multi-
protein complex and regulates the substrate translocation into
the lumen of the lysosome where substrate will be degraded
(Bandyopadhyay et al., 2008). The translocation of the substrate
across the lysosomal membrane requires the presence of a
specific form of hsc70 resident in the lysosomes (lys-hsc70)
which, at the end of the process, actively disassembles lamp2A
into monomers to initiate a new cycle of substrate uptake and
degradation (Agarraberes and Dice, 2001; Bandyopadhyay et al.,
2008). Consequently, the rate of CMA can be modulated by the
rate of assembly/disassembly of the translocation complex and,
for this reason, lamp2A could be considered the rate-limiting
protein of the process (Figure 1A).
Although CMA can assume some tissue-specific functions
(discussed below), this pathway carries out two main general
functions in all cell types and, indeed, basal levels of CMA
activity can be detected in almost all cells. The first role proposed
for CMA is an involvement in amino acids recycling during
starvation, a stress condition characterized by energy depletion.
In this circumstance, CMA is strongly activated to break down
non-essential substrates to sustain synthesis of vital proteins
in the absence of nutrients (Cuervo et al., 1995a). The other
important cellular function of CMA is protein quality control
based on its ability to selectively remove specific proteins from
the cytosol. Indeed, different subunits of the catalytic core of the
proteasome have been shown to be degraded in lysosomes by this
pathway (Cuervo et al., 1995b). Moreover, CMA is the principal
catabolic process by which oxidized, aberrant and damaged
proteins, as well as proteins prone to aggregate, are removed
from the cell. For this reason, CMA is strongly up-regulated
during oxidative stress (Kiffin et al., 2004) or exposure to toxic
compounds (Cuervo et al., 1995a, 1999), and cells with reduced
CMA activity are more susceptible to oxidative agents (Massey
et al., 2006).
In addition to these general functions, CMA regulates other
cell type-specific functions such as antigen presentation in
immune cells (Zhou et al., 2005), control of renal tubular cells
growth through the degradation of the Pax2 transcription factor
(Sooparb et al., 2004), and preservation of neuronal viability
(Yang et al., 2009). In particular, the selective degradation of a
neuronal survival transcriptional factor, myocyte enhancer factor
2D (MEF2D) has been described to be ascribable, at least in part,
to CMA and this represents a fundamental mechanism to ensure
an adequate neuronal response to injury (Yang et al., 2009).
Indeed, many evidences directly sustain a MEF2D involvement
in PD pathogenesis: reduced MEF2D levels were observed in
brains of patients, in PD animal models and in response to asyn
accumulation and aggregation (Yang et al., 2009; Chu et al.,
2011), although unchanged MEF2D expression was observed in
lymphomonocytes obtained from PD patients (Sala et al., 2014).
Moreover, She et al. (2011) identified a mitochondrial form of
MEF2D with decreased levels in PD brains and in animal models
that were treated with PD-related toxins. The exact mechanisms
for MEF2D alterations that leads to neurodegeneration are still
largely unknown, but a possible contribution of oxidative stress
has been hypothesized. Indeed, 6-hydroxydopamine (6-OHDA)
is able to directly oxidizeMEF2D and increased oxidizedMEF2D
levels were observed in PD brains (Gao et al., 2014). Moreover,
oxidized MEF2D binds hsc70 with higher affinity (Gao et al.,
2014), and oxidative stress induces lamp2A up-regulation that
in turn increases MEF2D degradation (Kiffin et al., 2004). The
role of MEF2D down-regulation in the pathogenesis of PD is
also confirmed by the evidence that PD-related toxins reduce
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FIGURE 1 | Chaperone-mediated autophagy (CMA) in physiology (A) and in Parkinson’s disease (PD)-related conditions (B). (A) A proper CMA activity
contributes to the maintenance of the neuronal homeostasis; (B) different alterations related to familial or sporadic PD forms impair CMA and significantly contribute
to neuronal death: (1) mutant A30P and A53T asyn bind to lamp2A with a higher affinity, thus inhibiting the binding of other substrates; (2) mutant I93M UCHL-1
abnormally interacts with lamp2A causing asyn accumulation; (3) mutant LRRK2 prevents lamp2A multimerization and consequently, the translocation of substrates;
(4) mutant GBA may increase the levels of wild-type asyn resulting in a block of CMA due to an excess of substrates; (5) PTM (post-translational-modified)-asyn
forms, including dopamine-modified, oxidized, phosphorylated and nitrated asyn, inhibit CMA-mediated degradation of asyn and other substrates.
the expression of this neuronal transcription factor (Wang
et al., 2014), and a potential pharmacological strategy using
activators of MEF2D ameliorates the pathological outcome in
PD animal models (Yao et al., 2012). The possible beneficial role
of MEF2D induction was also confirmed in an in vitro model
after an acute treatment with low doses of the mitochondrial
complex I inhibitor rotenone: a de novo synthesis of MEF2D
was observed to increase the nuclear fraction of this pro-survival
factor to compensate the mild cellular damage (Sala et al.,
2013).
ALTERATIONS OF CMA IN PD
Effect of PD-Related Genetic Mutations on
CMA
For years, PD was considered a pure sporadic disease caused
by environmental factors such as chemicals and head injuries.
However, it was increasingly clear that environmental factors
were not enough to cause the disease. SNCA, which encodes
for asyn, was the first gene discovered to be associated to
autosomal dominant forms of PD. Actually, single nucleotide
variants, duplications and triplications on the asyn gene cause
an early onset of the disease (Polymeropoulos et al., 1997;
Singleton et al., 2003; Chartier-Harlin et al., 2004). In particular,
the overexpression rate was correlated to the disease’s severity,
with patients carrying a triplication of SNCA gene developing a
more severe form of the disease (Singleton et al., 2003) than the
duplication cases. Later on, other mutations were identified to
cause familial forms of PD. Among them, transgenic cellular and
animal models demonstrated an association of such mutations
to dysfunctions of CMA. Mutant A30P and A53T asyn bind
to lamp2A with a higher affinity without being internalized
and degraded, thus preventing the binding of other substrates
(Cuervo et al., 2004). Pathogenic mutations of the leucine-rich
repeat kinase 2 (LRRK2), including the most common G2019S
mutant, can block CMA by inhibiting the translocation complex
at the lysosome membrane (Orenstein et al., 2013). The net
result of both these aberrant interactions is the accumulation of
toxic substrates leading to a generalized cellular stress. Abnormal
interaction with CMA components, including lamp2A and the
chaperones hsc70 and heat shock protein 90 (hsp90), has been
also demonstrated for the PD-associated I93M mutant ubiquitin
C-terminal hydrolase L1 (UCH-L1), which results in an increase
of asyn levels within cells due to a blockage of its degradation
via CMA (Kabuta et al., 2008). Recently, PARK7/DJ-1, a protein
implied in antioxidative defense and mitochondrial homeostasis
maintenance and whose mutations are responsible for autosomal
dominant forms of PD, has been identified as a substrate
of CMA (Wang et al., 2016). It has also been found that
inactive DJ-1 forms increase following CMA inhibition, and
this contributes to mitochondrial dysfunctions. In particular, it
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has been demonstrated that oxidized/non-functional DJ-1 forms
are preferentially degraded by this pathway. This consequently
can regulate mitochondrial function via maintaining DJ-1
homeostasis (Wang et al., 2016). Finally, emerging data suggest
a role for mutations of GBA gene in autophagy alterations.
GBA mutations cause Gaucher’s disease leading to a deficiency
of the lysosomal enzyme glucocerebrosidase (GCase) and they
are recognized as important risk factors for PD (Sidransky and
Lopez, 2012; Migdalska-Richards and Schapira, 2016). As a
matter of fact, the functional loss of GCase in primary cultures
or human iPS neurons causes accumulation of asyn which may
result in a CMA impairment (Mazzulli et al., 2011; Figure 1B).
Evidence for CMA Dysfunction in
Sporadic PD
The involvement of CMA in PD pathogenesis is not only
supported by genetic evidences but also alterations of CMA
parameters were also observed in sporadic forms of PD.
Post mortem brain samples from PD patients revealed a
down-regulation of both hsc70 and lamp2A in the substantia
nigra pars compacta and amygdala as compared to healthy
controls (Alvarez-Erviti et al., 2010). Furthermore, the selective
loss of lamp2A protein in early stages of PD correlated
with increased levels of asyn and other cytosolic CMA
substrate proteins (Murphy et al., 2015), suggesting that CMA
dysfunctions may precede asyn pathogenic accumulation in PD.
Interestingly, hsc70 down-regulation was also demonstrated in
peripheral lymphomonocytes of sporadic PD patients (Sala et al.,
2014; Papagiannakis et al., 2015). In these cells, a reduction
of lamp2 (not lamp2A) protein levels and an increase of the
autophagosome marker LC3-II were also reported (Prigione
et al., 2010; Wu et al., 2011). This suggests the existence
of a systemic alteration of autophagy in PD. Moreover, the
sequencing of genomic DNAs from leukocytes of sporadic
PD patients allowed the identification of a novel sequence
variant in a patient that significantly reduced the transcriptional
activities of lamp2 gene promoter (Pang et al., 2012). Since
lamp2A is the splicing isoform of lamp2 specific for CMA,
reduced levels of lamp2 may be reasonably associated to an
abatement of CMA activity. Recently, the potential role of
microRNAs (miRNAs) in the CMA down-regulation observed
in PD patients was also found. Indeed, the down-regulation of
hsc70 and lamp2A in PD brains has been shown to correlate
with an up-regulation of six miRNAs targeting the 3′ UTR
of hsc70 or lamp2A (Alvarez-Erviti et al., 2013). However,
currently there is a dearth of study material regarding the
role of ‘‘CMA miRNAs’’ in PD pathogenesis apart from the
only one study that showed the up-regulation of one of them
resulted in the knock-down of hsc70 and increased levels
of asyn in human SH-SY5Y neuroblastoma cells (Li et al.,
2014).
Alterations of CMA in Cellular and Animal
Models of PD
Collectively, CMA alterations are considered as an important
pathogenic mechanism responsible in nigral neuronal death,
even though the underlying molecular mechanisms are not yet
fully explained. CMA impairment may favor the processes that
are known to play a major role in PD pathology, such as
asyn toxicity, mitochondrial dysfunction and oxidative stress,
which in turn have been demonstrated to negatively influence
autophagy activity, thus originating a vicious circle whose final
outcome is the death of dopaminergic neurons (Bandopadhyay
and de Belleroche, 2010).
The expression of A53T mutant asyn is able to cause a CMA
impairment, as observed in adenoviral transfected PC12 and
SH-SY5Y cells (Xilouri et al., 2009). Such impairment leads
to a global lysosomal dysfunction that may be counteracted
by a compensatory up-regulation of macroautophagy.
Experimental models of selective CMA blockage also support
the potential fundamental role of CMA in PD pathogenesis. The
down-regulation of lamp2A receptor resulted in an increased
sensitivity to oxidative stressors in mouse fibroblasts (Massey
et al., 2006) and in the accumulation of soluble high molecular
weight and detergent-insoluble species of asyn in PC12 and
SH-SY5Y cells (Vogiatzi et al., 2008). Lamp2A down-regulation
also causes a raise in autophagic vacuoles within rats nigral
neurons with a progressive loss of the same neurons as well
as unilateral motor behavioral deficits (Xilouri et al., 2016).
However, other studies failed to report CMA dysfunctions
after lamp2 silencing, and a compensatory activation of
other proteolytic pathways was reported after the aspecific
down-regulation of all lamp2 isoforms (Eskelinen et al., 2004;
Rothaug et al., 2015). Recently, it has been observed that RNA
interference against hsc70 results in an up-regulation of asyn
mRNA and protein levels, a condition that is likely to favor
protein accumulation and aggregation typical of PD (Sala et al.,
2016), suggesting again that the observed down-regulation of
CMA effectors observed in PD brains may be a key-condition
for a deadly accumulation of toxic substrates, especially asyn,
within dopaminergic neurons. Post-translational modifications
of wild-type asyn, such as oxidation, phosphorylation and
nitration, are known to alter CMA activity, thus resulting in an
inhibition of CMA-mediated asyn degradation, while dopamine-
modification of asyn also impairs the degradation of other CMA
substrates (Martinez-Vicente et al., 2008; Figure 1B). These
modifications were largely found in PD brains (Fujiwara et al.,
2002; Anderson et al., 2006) as well as in peripheral samples
from patients (Prigione et al., 2010; Foulds et al., 2011).
Furthermore, PD-related toxins, such as rotenone and
paraquat, are able to induce alterations of CMA effectors
and substrates. Actually, midbrains of paraquat-treated mice
showed a CMA activation, as indicated by increased levels
of lamp2A and hsc70, and an enhanced lysosomal clearance
of asyn (Mak et al., 2010). On the contrary, exposure to the
pesticide rotenone caused an up-regulation of asyn in SH-SY5Y
cells (Sala et al., 2013) and a down-regulation of hsc70 in
SH-SY5Y cells and mouse cortical neurons (Sala et al., 2016).
These different results may be explained by the mechanisms
of action of rotenone, a mitochondrial complex I inhibitor,
and paraquat, an oxidative stress donor. As a matter of fact,
CMA seems to be up-regulated in oxidative stress conditions,
in order to participate in the removal of oxidized proteins.
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Rats exposed to sub-lethal doses of paraquat or 6-OHDA
showed a significant increase in the expression of lamp2A
and hsp90 (Kiffin et al., 2004; Marin and Aguilar, 2011) that
can be interpreted as a cellular conservative mechanism for
the removal of oxidized proteins. Impaired macroautophagy
in knocked-out Atg5 mouse embryonic fibroblasts resulted in
an up-regulation of CMA (Kaushik et al., 2008) that exerts a
protective role against toxicity induced by menadione and UV
light but not by staurosporine and endoplasmic reticulum stress
(Wang et al., 2008). Similarly, up-regulation of CMA in Atg5 null
murine embryonic fibroblasts increased cellular resistance to
photokilling, while CMA-deficient cells were protected against
the endoplasmic reticulum stressor thapsigargin (Dewaele et al.,
2011). Collectively, these findings unveil a cytoprotective role of
CMA against specific stressors with a dominant role of scavenger
of oxidized proteins, a pivotal self-preserving function for the
nigral dopaminergic neurons.
UP-REGULATION OF CMA AS POTENTIAL
THERAPEUTIC STRATEGY FOR PD
Given the evidences of the critical role of CMA activity
in controlling the levels of potentially toxic substrates, the
up-regulation of such autophagic pathway represents a new
challenge for the development of therapeutic strategies for
PD and other neurodegenerative disorders characterized by
protein accumulation, such as Alzheimer’s disease, amyotrophic
lateral sclerosis and Huntington’s disease. Early attempts with
chemical modulators identified small molecules that are able to
induce CMA such as 6-aminonicotinamide and geldanamycin,
inhibitors of the glucose-6-phopshate dehydrogenase or hsp90,
respectively (Finn et al., 2005). More recently, it has been
demonstrated that signaling through retinoic acid receptor
alpha (RARalpha) inhibits CMA and synthetic derivatives of
all-trans-retinoic acid reverse this inhibitory effect protecting
cells against oxidation and proteotoxicity (Anguiano et al., 2013).
Another promising strategy for CMA induction involves the
direct overexpression of lamp2A. In a first attempt on transgenic
mice, up-regulating the lysosomal receptor of CMA improved
liver function and slowed-down cellular damage associated
with proteotoxicity (Zhang and Cuervo, 2008). This paradigm
has been recently applied to in vitro and in vivo neuronal
systems. Lamp2A overexpression in human neuroblastoma
SH-SY5Y cells and rat primary cortical neurons protected
cells from asyn-induced neurotoxicity (Xilouri et al., 2013a).
Similarly, this strategy restored the asyn-mediated nigrostriatal
degeneration and reduced total asyn levels as well as the
generation of aggregated and phosphorylated asyn forms in
rats (Xilouri et al., 2013a). The up-regulation of lamp2A may
also be obtained through the modulation of miRNAs. For
example, miR-21 overexpression down-regulates the expression
of lamp2A (Alvarez-Erviti et al., 2013), while its inhibition
up-regulates lamp2A levels and reduces asyn levels in SH-SY5Y
cells and MPTP-induced PD mice (Su et al., 2016). Finally, given
its role as CMA carrier and its anti-aggregant properties on asyn
(Pemberton et al., 2011; Pemberton and Melki, 2012), hsc70 may
represent a further potential target for PD therapeutic strategies,
but no studies have yet explored such possibility.
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